<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574885</url>
  </required_header>
  <id_info>
    <org_study_id>AEROSAL3</org_study_id>
    <nct_id>NCT01574885</nct_id>
  </id_info>
  <brief_title>Efficacy of Aerosal速 in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases</brief_title>
  <official_title>Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal速 in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecno Sun SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Studi Gised</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tecno Sun SRL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Aerosal速 compared to a placebo
      treatment in the prognosis of sub-obstructive adenotonsillar hypertrophy present for at least
      six months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline of adenotonsillar hypertrophy degree equal to or greater than 25%</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hypoacusis equal to or greater than 10 dB</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Change from baseline of hypoacusis equal to or greater than 10 dB, detected at the frequencies of the tone range (5, 10, 20, 40 KHz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of tympanometry curve</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Any change from baseline of tympanometry, defined as the passage from curve type B to curve type C/A or from curve type C to curve type A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of adenotonsillar hypertrophy degree</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of basal SpO2% levels</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Any change from baseline of basal SpO2% mean levels as assessed by pulse-oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of apnea index</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Any change from baseline of apnea events in an hour (apnea index), as assessed by pulse-oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of sleep time percentage with SpO2&lt;95%</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Any change from baseline of sleep time percentage with SpO2 levels under 95%, as assessed by pulse-oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any change from baseline of hypoacusis</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Any change from baseline of hypoacusis, detected at the frequencies of the tone range (5, 10, 20, 40 KHz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reported adverse events</measure>
    <time_frame>2 weeks (10 sessions), 14 weeks</time_frame>
    <description>Number of reported adverse events (AEs) during treatment period or after the end of treatment, if suspected to be related with it</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Aerosal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm include all patients treated with Aerosal速</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm include all patients treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Halotherapy</intervention_name>
    <description>The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.</description>
    <arm_group_label>Aerosal</arm_group_label>
    <other_name>aerosal</other_name>
    <other_name>salt</other_name>
    <other_name>sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sub-Obstructive Adenotonsillar Hypertrophy lasting from at least six months and
             associated with sleep disordered breathing (respiratory pauses or sleep-apnea) and/or
             recurrent sero-mucus otitis

          -  Suspension for more than 3 months from the date of any immunosuppressive treatments
             (cyclosporin, systemic steroids)

        Exclusion Criteria:

          -  Patients with acute bronchopulmonary disease, tuberculosis, severe hypertension,
             hyperthyroidism, cancer (chemotherapy), intoxication, heart failure, bronchial asthma.

          -  Iodine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matteo Gelardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University General Hospital Consortium of Bari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital Consortium</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>adenotonsillar hypertrophy</keyword>
  <keyword>salt</keyword>
  <keyword>sodium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

